ABUSArbutus Biopharma Corporation

$4.20-5.2% 1Y

What is the market doing?

Mixed

No clear lean: nothing decisive, though a crowded short (+17% of shares).

1 to watch, 1 neutral, 1 without data
TrendRangeboundderived · Oct 23, 2026

Rangebound, no clear trend. Oversold (RSI 29). Price is −7% vs its 200-day average.

Short interest17% of sharesFINRA · Sep 30, 2026

A crowded short, settled Sep 30, 2026, about a week of normal trading to cover.

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How ABUS is trading

Arbutus Biopharma Corporation is −5.2% over the past year while the S&P 500 is +16%: 21 points behind the market.

−5.2%

1-year return · S&P 500 +16%

vs 200-day average
−6.8%

vs 200-day average · below trend, but not far

RSI (14)
29

RSI (14) · oversold, sold harder than it has been bought

Below its 52-week high
19%

Below its 52-week high

Oct 21, 2024$2.88 – $5.20 · dashed line: 200-day averageOct 23, 2026
Details›
Last close2026-10-23
$4.20
1 monthS&P 500 −0.94%
−14%
1 yearS&P 500 +16%
−5.2%
5 yearsS&P 500 +86%
+2.9%
vs 50-day average$4.76
−12%
52-week high
$5.20
52-week low
$3.67
Annualised volatility
44%
Calendar-year price return
YearReturn
2026 (year to date)−13%
2025+47%
2024+31%
2023+7.3%
2022−40%
2021+9.6%
2020+28%
2019−27%
2018−24%
2017+106%
Average return by calendar month, 2016–2026
MonthYearsPositiveAverage
Jan105 of 10−1.0%
Feb108 of 10+7.9%
Mar103 of 10−9.0%
Apr106 of 10−2.5%
May105 of 10+6.9%
Jun106 of 10+2.9%
Jul115 of 11+13%
Aug115 of 11−0.03%
Sep116 of 11+8.0%
Oct112 of 11−8.3%
Nov105 of 10+4.0%
Dec104 of 10+6.1%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.

Where the price stands

Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.

What it has returned

With dividends, year by year, month by month, and by calendar month on average.